Medigene–Leucadia: investor conference, 201906 supply service Medigene presents at Jefferies Global Healthcare Conference NY

	Period	2019-06-04 ï¿½ 2019-06-07
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	Medigene AG (FSE: MDG1, Prime Standard)
	Group	Medigene (Group)
	Partner, 2nd	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2019 Global Healthcare Conference New York
	Product 2	TCR engineered T-cells
	Person	Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
	Person 2	Hofmann, Julia (MC Services 201910– before Medigene)

Medigene AG. (5/8/19). "Press Release: Medigene Participates at Upcoming Conferences". Martinsried.

Medigene AG (FSE: MDG1, Prime Standard) today announced its participation at the following upcoming scientific, business development and investor conferences:

EACR-ESMO Joint Conference on Liquid Biopsies
Date: 15 - 17 May 2019
Location: Bergamo, Italy

CIMT Annual Meeting
Date: 21 - 23 May 2019
Location: Mainz, Germany
Prof. Dolores J. Schendel, CEO of Medigene AG, will give a presentation on the topic "Matching future needs for world patient populations needing TCR-T therapies with different antigen specificities and HLA restrictions" on 23 May.

ASCO - American Society of Clinical Oncology - Annual Meeting
Date: 01 - 05 June 2019
Location: Chicago, USA

BIO International Convention
Date: 03 - 06 June 2019
Location: Philadelphia, USA

Jefferies Global Healthcare Conference
Date: 04 - 07 June 2019
Location: New York/USA
Prof. Dolores J. Schendel, CEO of Medigene AG, is invited to give a company presentation.

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com